Our Company Features
Most advanced adhesion and delivery system
Proprietary patch technology optimizes drug delivery through the skin.
Anti-inflammatory oral solution delivers individualized dosing
Precision dosing in high risk patients.
The only liquid ready-to-use analgesic formulated in a proprietary delivery system
Delivers fast and long lasting migraine relief.
About Us
Leader in non-opioid pain management products
Scilex Holding Company (Nasdaq: SCLX) is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and becoming the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products that maximize quality of life.
About Us
Leader in non-opioid pain management products
Scilex Holding Company (Nasdaq: SCLX) is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life.
Product Portfolio
OPTIMIZE QUALITY OF LIFE THROUGH PHARMACEUTICALS
Testimonals
Topical Delivery Systems Effectively Transport Analgesics to Areas of Localized Pain via Direct Diffusion
Pain Freedom With Celecoxib Oral Solution, Ubrogepant, and Rimegepant Through 4 Hours Postdose
Corporate Presentation
Scilex Holding Company Corporate Presentation
Download here »
December 10, 2024
NeuroBiogen Company and Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company enter into Binding Term Sheet for Worldwide License, Along with the Rights to Sublicense for All of KDS2010 indications; Binding Term Sheet Includes Collaboration for Development and Commercialization of Novel Oral Tablet KDS2010 in Ongoing Phase 2 CardioMetabolic and Neurodegenerative Diseases
Read More »December 10, 2024
Scilex Holding Company Enters into a Binding Term Sheet for a Joint Venture with IPMC and Bio Open Innovation Consortium to Develop and Commercialize a Phase 2 Clinical Stage, Potential Best-In-Class Novel Oral Tablet for the Treatment of Obesity and Neurodegenerative Diseases Including Alzheimer’s Disease
Read More »Do you have any questions? Lets talk!
650-516-4310